New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds - The New York Times

0

31.03.2022 01:45

Google.com 

1. New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds  The New York Times
2. Tracking the FDA advisory panel on Amylyx Pharma's ALS treatment  STAT
3. FDA advisory vote casts pall over the future of Amylyx’s experimental ALS drug  The Boston Globe
4. FDA panel votes against recommending new ALS drug, for now  CNBC Television
5. View Full Coverage on Google News

Moscow.media

Частные объявления сегодня

Rss.plus

Все новости за 24 часа